Julia Qu

Associate Professor of Immunology and Immune Therapeutics

Image of Julia Qu
Is this your profile? Click to edit

Overview

The research in the Qu lab focuses on lung immunity, inflammation, and diseases, spanning acute injury, chronic conditions, infectious diseases, and lung cancer—the leading cause of cancer-related mortality worldwide. Using mouse and human co-clinical models and state-of-the-art technologies, the Qu group is trying to elucidate the cellular and molecular mechanisms underlying lung homeostasis and diseases development, progression, and therapy resistance, for preventive, prognostic, and therapeutic purposes, and is developing innovative therapies for lung cancer, the most devastating cancer type.

As the primary organ for gas exchange, the lung constantly encounters challenges from the external environment. The lung immune system, particularly the innate immunity, plays a crucial role in guarding the lung against these threats and maintaining lung homeostasis. The Qu research team is investigating the mechanisms underlying pulmonary immune regulation and its deregulation, particularly the innate immune components, in promoting lung inflammation and disease development and progression. At the cellular level, they mainly focus on lung epithelial cells and macrophages, the key sentinels in the lung and the main culprits of lung diseases. At the molecular level, they mainly focus on NF-κB and STAT signaling pathways, master regulators of cell survival, proliferation, and immunity.

Research Funding

  • The NF-kappaB modulator PDLIM2 as an intrinsic checkpoint of alveolar macrophages critical for lung innate immunity, inflammation and diseases
    NIH · R01HL177140 · Apr 1, 2025 – Jan 31, 2029 · Role: Principal Investigator
  • Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis
    NIH · R01CA258614 · Aug 24, 2022 – Jul 31, 2027 · Role: Principal Investigator
  • Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases
    NIH · R01GM144890 · Mar 10, 2022 – Feb 28, 2026 · Role: Principal Investigator
  • Clinicopathological significance of PDLIM2 in HIV/AIDS-related malignancies caused by KSHV
    NIH · R21CA189703 · Jul 1, 2015 – Jun 30, 2018 · Role: Principal Investigator

Publications

  • NanoPDLIM2-Based Combination Therapy for Lung Cancer Treatment in Mouse Preclinical Studies. Bio Protoc. 2025 Sep 05; 15(17):e5437.. View in PubMed
  • Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy. J Immunother Cancer. 2025 Jul 23; 13(7).. View in PubMed
  • Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. Elife. 2024 Dec 24; 12.. View in PubMed
  • PDLIM2 is a novel E5 ubiquitin ligase enhancer that stabilizes ROC1 and recruits the ROC1-SCF ubiquitin ligase to ubiquitinate and degrade NF-κB RelA. Cell Biosci. 2024 Jul 30; 14(1):99.. View in PubMed
  • NF-κB1 deficiency promotes macrophage-derived adrenal tumors but decreases neurofibromas in HTLV-I LTR-Tax transgenic mice. PLoS One. 2024; 19(5):e0303138.. View in PubMed
  • Critical and distinct roles of cell type-specific NF-κB2 in lung cancer. JCI Insight. 2024 02 22; 9(4).. View in PubMed
  • NF-κB RelA is a cell-intrinsic metabolic checkpoint restricting glycolysis. Cell Biosci. 2024 Jan 20; 14(1):11.. View in PubMed
  • Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. bioRxiv. 2024 Jan 09.. View in PubMed
  • Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021 12 20; 20(1):171.. View in PubMed
  • PDLIM2: Signaling pathways and functions in cancer suppression and host immunity. Biochim Biophys Acta Rev Cancer. 2021 12; 1876(2):188630.. View in PubMed